Razadyne ER

← The FDA Ephemeris: the whole map

Razadyne ER galantamine hydrobromide

Listed: the approval is known from Drugs@FDA; its review documents are not yet in the Ephemeris.

Application: NDA 21615
Sponsor: Janssen Pharmaceuticals
Drug class: Cholinesterase inhibitor
First approved: April 1, 2005
Drugs@FDA status: Discontinued

NDA 21615 on Drugs@FDA

Also cholinesterase inhibitors: Cognex, Aricept, Exelon, Razadyne, Aricept ODT, Adlarity, Zunveyl

From FDA documents. Not medical advice.

Anti-amyloid antibody

Aduhelm aducanumab-avwa
Leqembi lecanemab-irmb
Kisunla donanemab-azbt
Leqembi Iqlik lecanemab-irmb, subcutaneous

Regulatory records

Cholinesterase inhibitor

Cognex tacrine hydrochloride
Aricept donepezil hydrochloride
Exelon rivastigmine tartrate
Razadyne galantamine hydrobromide
Aricept ODT donepezil hydrochloride
Razadyne ER galantamine hydrobromide
Adlarity donepezil hydrochloride
Zunveyl benzgalantamine gluconate

NMDA receptor antagonist

Namenda memantine hydrochloride
Namenda XR memantine hydrochloride

Amyloid PET imaging agent

Amyvid florbetapir f-18
Vizamyl flutemetamol f-18
Neuraceq florbetaben f-18

Combination

Namzaric donepezil hydrochloride; memantine hydrochloride

Atypical antipsychotic

Rexulti brexpiprazole

Tau PET imaging agent

Tauvid flortaucipir f-18

Group by

Build queue · replay at pipeline speed